Dr. Elias Obeid on Androgen Receptor Expression in Triple-Negative Breast Cancer
Summary
TLDRThis study reveals significant findings in triple-negative breast cancer treatment. It reports estrogen receptor expression at 17%, aligning with previous studies that suggest a 15-20% range. The research, the largest dataset to date, also highlights overexpression of EGFR and HER2 in antigen receptor-negative cancers, suggesting potential targeted therapies like EGFR inhibitors or PI3 kinase inhibitors. In androgen receptor-positive cancers, low expression of TS and TOP2A with overexpression of other genes indicates the potential use of 5-FU, capecitabine, or taxanes. These insights pave the way for more personalized and effective treatment strategies.
Takeaways
- 🔬 The study found that estrogen receptor expression is present in about 17% of cases, which is consistent with previous studies that reported 15-20%.
- 📊 This is the largest dataset analyzed for this condition, making it a significant contribution to the field.
- 🚫 In triple negative breast cancers, also known as quadruple negative, there is an overexpression of EGFR and HER2, along with a loss of P-cadherin.
- 🎯 The presence of these markers suggests the potential for targeted therapy, specifically EGFR-targeted treatments like cyclins or PI3 kinase inhibitors.
- 🧬 In androgen receptor positive triple negative breast cancer, there is a low expression of TS and TOP2A, with an overexpression of other genes.
- 💊 This finding points to the use of alternative treatments such as 5-FU or capecitabine, which are fluoropyrimidines, for this group of patients.
- 🩺 The identification of different gene expressions in various subtypes of triple negative breast cancer allows for personalized treatment strategies.
- 🛑 Targeted therapies can now be considered for estrogen receptor positive breast cancers, in addition to standard chemotherapy.
- 🧬 The study emphasizes the importance of genetic profiling in guiding treatment options for breast cancer patients.
- 📈 The data from this study could lead to more effective treatment plans and potentially better outcomes for patients with breast cancer.
- 🔑 Understanding the genetic landscape of breast cancer is crucial for developing new and more precise therapeutic approaches.
Q & A
What percentage of estrogen receptor expression was found in the current study?
-Estrogen receptor expression was found in about seventeen percent of the cases in the current study.
What is the significance of the current study in comparison to previous studies?
-The current study is the largest dataset so far regarding estrogen receptor expression, making it a significant contribution to the field.
What are antigen receptor negative triple negative breast cancers also known as?
-Antigen receptor negative triple negative breast cancers are also referred to as quadruple negative breast cancers.
What overexpression was found in quadruple negative breast cancers in comparison to estrogen receptor positive breast cancers?
-In quadruple negative breast cancers, there was an overexpression of EGFR and HER2 along with a loss of PTEN compared to estrogen receptor positive breast cancers.
What targeted therapy could be considered for quadruple negative breast cancers based on the study findings?
-Targeted therapy like EGFR targeted treatments, which may include the use of cyclins or PI3 kinase inhibitors, could be considered for quadruple negative breast cancers.
What is the expression status of TS and TOP2A in androgen receptor positive triple negative breast cancer according to the study?
-In androgen receptor positive triple negative breast cancer, there is a low expression of TS and TOP2A.
Which other genes were found to be overexpressed in androgen receptor positive triple negative breast cancer?
-The study found that other unspecified genes were overexpressed in androgen receptor positive triple negative breast cancer.
What types of treatments could be used for androgen receptor positive triple negative breast cancer based on the study?
-Treatments such as 5-FU, capecitabine, or taxanes could be used for androgen receptor positive triple negative breast cancer.
How does the study suggest approaching treatment for estrogen receptor positive breast cancer?
-The study suggests targeting estrogen receptor positive breast cancer patients with targeted agents as well as combination therapy with other chemotherapeutic agents.
What does the term 'targeted therapy' refer to in the context of this study?
-In the context of this study, 'targeted therapy' refers to treatments that specifically aim at molecular pathways or proteins that are overexpressed or mutated in cancer cells, such as EGFR or PI3 kinase.
What is the implication of the findings for future research and treatment strategies for breast cancer?
-The findings imply that future research and treatment strategies for breast cancer could focus on identifying specific molecular markers and using targeted therapies or combination therapies to treat different subtypes of breast cancer more effectively.
Outlines
🧬 Genetic Expression in Triple Negative Breast Cancers
This paragraph discusses the findings from a significant dataset on the genetic expression in triple negative breast cancers. It highlights that estrogen receptor expression is present in about 17% of cases, which is consistent with previous studies that reported a range of 15% to 20%. The study also introduces the concept of 'quadruple negative' breast cancers, where overexpression of EGFR and loss of PTEN are observed. This discovery suggests potential targeted therapies, such as EGFR inhibitors or PI3 kinase inhibitors, for this group of patients. Additionally, the paragraph touches on the treatment options for androgen receptor positive triple negative breast cancer, where low expression of TS and TOP2A and overexpression of other genes indicate the potential use of treatments like 5-FU, capecitabine, or taxanes.
Mindmap
Keywords
💡Engine Receptor Expression
💡Triple Negative Breast Cancer
💡EGFR
💡PI3 Kinase
💡TS and TOP2A
💡Androgen Receptor Positive
💡5-FU
💡Capecitabine
💡Flouropyrimidines
💡Taxanes
💡Targeted Therapy
Highlights
Engine receptor expression is present in about seventeen percent in the current study.
Previous studies reported engine receptor expression between fifteen to twenty percent.
This study is the largest dataset known for engine receptor expression.
Antigen receptor negative triple negative breast cancers, also known as quadruple negative breast cancers.
Overexpression of EGFR and loss of PECAN in antigen receptor negative triple negative breast cancers.
Potential targeted therapy for EGFR overexpression in these cancers.
Use of cyclins or PI3 kinase for EGFR targeted treatments.
Androgen receptor positive triple negative breast cancer has low expression of TS and TOP3.
Overexpression of other genes in androgen receptor positive triple negative breast cancer.
Other treatments such as 5-FU or Capecitabine for androgen receptor positive triple negative breast cancer.
Taxanes can be used for this group of patients.
Targeting patients with targeted agents and combination therapy.
Combination therapy with other chemotherapeutic agents.
Opening the door for new targeted therapies in breast cancer treatment.
Significant findings in the largest dataset for breast cancer studies.
Implications for personalized medicine in breast cancer treatment.
Transcripts
why
what we found was that similar to other
previous studies engine receptor
expression is present in about seventeen
percent in this current study and the
others have been reported in about
fifteen to twenty percent our study is
the largest data set so far that we know
about so this is one of their the
findings second in antigen receptor
negative triple negative breast cancers
will also call the quadruple negative
breast cancers we found that
overexpression of egfr dopey 2a and loss
of pecan seem to be present in
comparison to engineer receptor positive
breast cancers and this would open the
door for potentially looking at targeted
therapy like egfr targeted treatments
like the use of either cyclins or the
use of pi3 kinase for this particular
group now on the other hand in androgen
receptor positive triple negative breast
cancer we found that there is a low
expression of TS and top three and over
express and actually overexpression of
other genes basically therefore other
treatments such as 5-fu or Capeside
amine like the floral pyrimidines can be
used for this or taxes can be used for
this particular a group of of patients
and as I mentioned those are engineers
at the positive so basically we can now
think about targeting those patients
with the targeted agent as well as
combination therapy by you know some
other chemotherapeutic agents
Ver Más Videos Relacionados
How to Treat Stage II (2) Breast Cancer: All You Need to Know
Heart failure- NICE guideline
Immunotherapy Treatments for Non-Small Cell Lung Cancer (NSCLC)
Adjuvant Osimertinib and Advanced EGFR-Mutated NSCLC | NEJM
Enhance Your Androgen Receptors The Role of Semen Retention, Bone Density, and Lifestyle Factors
Delivering Bad News - What not to do...
5.0 / 5 (0 votes)